Northern Institute for Cancer Research Newcastle Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2018
NCT03781934
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Northern Institute for Cancer Research Newcastke

Active Ingredients

Drugs in Phase 2 Trials (1)

Fostroxacitabine bralpamide (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Hepatocellular (Phase 2)

Cholangiocarcinoma (Phase 2)

Liver Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1